Agonistes des récepteurs du GLP-1 : ­impact sur la maladie rénale diabétique.

semaglutide; Hypoglycemic Agents; Glucagon-Like Peptides; Glucagon-Like Peptide-1 Receptor Agonists; Humans; Hypoglycemic Agents/therapeutic use; Hypoglycemic Agents/pharmacology; Glucagon-Like Peptides/therapeutic use; Glucagon-Like Peptides/pharmacology; Cardiovascular Diseases/prevention & control; Renin-Angiotensin System/drug effects; Renin-Angiotensin System/physiology; Diabetic Nephropathies/drug therapy; Diabetes Mellitus, Type 2/drug therapy; Diabetes Mellitus, Type 2/complications; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucagon-Like Peptide-1 Receptor; Renin-Angiotensin System; Medicine (all)

Abstract :

[en] In addition to optimal glycemic control and management of other factors aggravating the pathology (hypertension, dyslipidemia, -obesity), the cornerstone of treatment of diabetic kidney disease (DKD) includes blockers of the renin-angiotensin system, sodium-glucose cotransporter 2 inhibitors or nonsteroidal antagonists of the mineralocorticoid receptor (finerenone). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are recommended in the treatment of high-risk patients with type 2 diabetes (T2DM) to reduce cardiovascular (CV) risk. Data from CV studies indicate a nephroprotective effect of certain GLP-1 RAs in T2DM patients with DKD. The FLOW study published in May 2024, analyzing the impact of semaglutide vs placebo on renal events as primary outcome, confirms this renal protection of GLP-1 RAs.
[fr] Outre le contrôle glycémique et la prise en charge d’autres facteurs d’aggravation de la pathologie, la pierre angulaire du traitement de la maladie rénale diabétique (MRD) comprend les bloqueurs du système rénine-angiotensine, les inhibiteurs du cotransporteur sodium-glucose de type 2 ou encore la finérénone (antagoniste de l’aldostérone). Les agonistes du récepteur du glucagon-like peptide-1 (ARGLP-1) sont recommandés dans le traitement des patients avec un diabète de type 2 (DT2) à haut risque afin de réduire le risque cardiovasculaire (CV). Les données provenant des études CV indiquent un effet néphroprotecteur de certains ARGLP-1 chez les patients DT2 avec MRD. L’étude FLOW, publiée fin mai 2024 et analysant l’impact du sémaglutide sur les événements rénaux comme critère principal, confirme cette protection rénale des ARGLP-1.

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

Wera, Madeleine ; Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques

Paquot, Nicolas ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladies métaboliques

Language :

French

Title :

Agonistes des récepteurs du GLP-1 : impact sur la maladie rénale diabétique.

Alternative titles :

[en] GLP-1 receptor agonists : impact on diabetic kidney disease.

Publication date :

28 August 2024

Journal title :

Revue Médicale Suisse

ISSN :

1660-9379

Publisher :

Editions Medecine et Hygiene, Switzerland

Volume :

Issue :

884

Pages :

1488 - 1491

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 30 June 2025

Statistics

Number of views

113 (1 by ULiège)

Number of downloads

114 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015 Jul 30;1:15018. DOI:10.1038/nrdp.2015.18.
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020 Feb 29;395(10225):709-33. DOI:10.1016/S0140-6736(20)30045-3.
Baena-Díez JM, Peñafiel J, Subirana I, et al. Risk of Cause-Specific Death in Individuals With Diabetes: A Competing Risks Analysis. Diabetes Care. 2016 Nov;39(11):1987-95. DOI:10.2337/dc16-0614.
Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013 Feb;24(2):302-8. DOI:10.1681/ASN.2012070718.
Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Sep 20;345(12):861-9.
Scheen AJ, Delanaye P. Inhibiteurs des SGLT2: focus sur le rein et la néphroprotection. Rev Med Suisse. 2021 Aug 25;17(747):1397-403. DOI:10.53738/revmed.2021.17.747.1397.
Philips JC, Radermecker RP. Gliflozines et finérénone: quelles perspectives pour leur association? Rev Med Suisse. 2023 Aug 23;19(838):1503-6. DOI:10.53738/revmed.2023.19.838.1503.
Scheen AJ, Paquot N. Traitement des patients diabétiques de type 2 à risque cardiorénal: ESC versus ADA-EASD. Rev Med Suisse. 2020 Aug 26;16(703):1478-82. DOI:10.53738/revmed.2020.16.703.1478.
Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024 May 24. DOI:10.1056/NEJMoa2403347.
King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): Clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999 Nov;48(5):643-8. DOI:10.1046/j.1365-2125.1999.00092.x.
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022 Nov;102(5S):S1-127. DOI:10.1016/j. kint.2022.06.008.
Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021 Apr;46:101102. DOI:10.1016/j.molmet.2020.101102.
Goldney J, Sargeant JA, Davies MJ. Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy. Diabetologia. 2023 Oct;66(10):1832-45. DOI:10.1007/s00125-023-05988-3.
Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycaemia In Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022 Dec;65(12):1925-66. DOI:10.1007/s00125-022-05787-2.
Mann JFE, Nauck MA, Nissen SE, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. Drug Ther Bull. 2016;54:101. DOI:10.1056/nejmoa1603827.
Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-44. DOI:10.1056/nejmoa1607141.
Shaman AM, Bain SC, Bakris GL, et al. Effect of the glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. Circulation. 2022 Feb 22;145(8):575-85. DOI:10.1161/CIRCULATIONAHA.121.055459.
Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021 Oct;9(10):653-62. DOI:10.1016/S2213-8587(21)00203-5.
Aviles Bueno B, Soler MJ, Perez-Belmonte L, et al. Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice. Clin Kidney J. 2022 Aug;15(8):1593-600. DOI:10.1093/ckj/sfac096.
Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med. 2021 Sep 2;385(10):896-907. DOI:10.1056/nejmoa2108269.
Górriz JL, Romera I, Cobo A, O’Brien PD, Merino-Torres JF. Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence With Practical Considerations. Diabetes Ther. 2022 Mar;13(3):389-421. DOI:10.1007/s13300-021-01198-5.